DSIP

What DSIP Does

DSIP (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits during electrically induced sleep by Schoenenberger and Monnier in 1977. It was named for its ability to promote delta wave (slow-wave) sleep when injected into recipient animals.

The mechanisms that matter for your protocol:

• Delta wave promotion — DSIP increases the amplitude and duration of delta waves (0.5–4 Hz) during NREM Stage 3 sleep. This is the deepest sleep stage, associated with the body’s largest growth hormone pulse, tissue repair, and immune reconstitution
• Neuroendocrine modulation — DSIP affects the release of ACTH, cortisol, and growth hormone. It appears to normalize the HPA axis, reducing stress-related cortisol elevation that disrupts sleep
• Stress buffering — DSIP has anxiolytic properties, reducing the physiological stress response that contributes to insomnia and poor sleep quality
• Circadian rhythm support — DSIP may help regulate circadian oscillations, supporting consistent sleep-wake cycling
• Opioid system interaction — DSIP interacts with the endogenous opioid system (met-enkephalin modulation), which plays a role in sleep regulation and pain perception

What DSIP Is NOT

DSIP is not a sedative. It does not “knock you out.” It modulates the architecture of sleep — increasing the proportion of deep, restorative sleep relative to lighter stages. You fall asleep naturally and wake naturally, but the sleep you get is deeper and more restorative.

This is fundamentally different from pharmaceutical sleep aids (Ambien, benzodiazepines, antihistamines) that sedate you into unconsciousness while actually suppressing the deep sleep stages that provide restoration.

The Sleep Architecture Problem

Why Deep Sleep Matters

Your sleep is divided into stages, each serving different functions:

Stage	Type	% of Night	Function
N1	Light NREM	5%	Transition, easily awakened
N2	Light NREM	45–55%	Memory processing, heart rate slows
N3 (Delta)	Deep NREM	15–25%	GH release, tissue repair, immune function, memory consolidation
REM	Rapid Eye Movement	20–25%	Dreaming, emotional processing, learning

The problem: Delta sleep declines sharply with age. By age 50, deep sleep duration is 50–60% less than at age 25. By 60, many adults get almost no delta sleep. This loss directly contributes to:

• Reduced growth hormone output (GH’s main release occurs during delta sleep)
• Impaired tissue repair and recovery
• Weakened immune function
• Cognitive decline and memory problems
• Increased daytime fatigue despite “adequate” hours in bed

DSIP targets this specific deficit — restoring delta sleep that aging diminishes.

Dosing Protocol

Standard Sleep Optimization

Parameter	Detail
Dose	100–300 mcg
Timing	30–60 minutes before bed
Route	Subcutaneous injection
Cycle	10–14 days on, 2–4 weeks off
Repeat	3–4 cycles per year, or as needed

Titration

Phase	Dose	Duration
Assessment	100 mcg pre-sleep	Days 1–3
Standard	200 mcg pre-sleep	Days 4–10
Maximum (if needed)	300 mcg pre-sleep	Days 11–14

Start low. Many users find 100–200 mcg sufficient. The goal is improved sleep quality, not sedation — if you feel excessively drowsy the next morning, reduce the dose.

Why Short Cycles?

DSIP’s effects on sleep architecture appear to persist after discontinuation — users often report improved sleep quality for weeks after a 10–14 day cycle. This “resetting” effect means continuous use is unnecessary and potentially counterproductive:

1. Short cycles are sufficient to establish improved sleep patterns
2. Off-periods prevent potential receptor adaptation
3. The carry-over effect provides ongoing benefit without ongoing injection

DSIP vs Other Sleep Compounds

Compound	Mechanism	Deep Sleep	Dependency	Next-Day Impairment	Duration of Use
DSIP	Delta wave modulation	Increases	None reported	None	Short cycles
Melatonin	Circadian timing	No direct effect	None	Minimal	Ongoing OK
MK-677	GH elevation (sustained)	Improves	None	Possible hunger	Ongoing OK
Zolpidem (Ambien)	GABA-A agonism	Suppresses	Yes	Yes	Short-term only
Benzodiazepines	GABA-A agonism	Suppresses	Yes (severe)	Yes	Short-term only
Trazodone	5-HT2A/histamine	Minimal effect	Mild	Mild	Ongoing OK
Magnesium	NMDA/GABA modulation	Mild improvement	None	None	Ongoing OK

Key insight: DSIP and pharmaceutical sleep aids work in opposite directions on deep sleep. Pharmaceuticals sedate (suppress deep sleep). DSIP enhances (promotes deep sleep). The choice depends on whether you need to fall asleep (circadian/onset issue) or need better quality sleep (architecture issue).

DSIP + MK-677 for Sleep

Both DSIP and MK-677 improve sleep quality through different mechanisms:

• DSIP directly promotes delta wave architecture
• MK-677 enhances sleep through sustained GH elevation

Some users combine DSIP (short cycles) with MK-677 (ongoing) for comprehensive sleep optimization. MK-677 provides the sustained baseline while DSIP’s short cycles provide periodic deep-sleep resets.

What to Expect

During a DSIP Cycle

Night	Typical Experience
1–2	Subtle. May notice slightly deeper sleep, more vivid dreams
3–5	Clearer improvement in sleep depth. Less mid-night waking. More refreshed upon waking
7–10	Consistent deep sleep improvement. Noticeable difference in daytime energy and recovery
11–14	Full effect. Deep, restorative sleep pattern established

After Stopping

Most users report 2–4 weeks of continued benefit after a cycle. Sleep quality gradually returns to baseline, at which point another cycle can be initiated.

Safety & Contraindications

Side Effects

DSIP has an excellent safety profile based on published research:

Side Effect	Frequency	Notes
Injection-site reaction	Common	Standard SC reaction
Morning drowsiness	Occasional	Dose-dependent, reduce if persistent
Vivid dreams	Common	Generally considered a positive effect

Contraindications

• Concurrent sedative use — while not a contraindication per se, combining DSIP with sedatives (benzodiazepines, opioids, alcohol) has not been studied. Use caution.
• Pregnancy/breastfeeding — no safety data
• Under 18 — no pediatric data
• Active neurological conditions — epilepsy, severe depression (DSIP affects neuroendocrine function; consult a neurologist)

Blood Work

No specific blood work is required for DSIP use at standard doses and cycle lengths. For users combining DSIP with GH peptides, follow the blood work recommendations for those protocols.

Research & Citations

Original discovery: Schoenenberger GA, Monnier M, “Characterization of a delta-electroencephalogram-sleep-inducing peptide,” Proceedings of the National Academy of Sciences (1977). The foundational paper isolating and characterizing DSIP.

Sleep architecture: Graf MV, Kastin AJ, “Delta-sleep-inducing peptide (DSIP): a review,” Neuroscience & Biobehavioral Reviews (1984). Comprehensive review of DSIP’s effects on sleep stages and neuroendocrine function.

Stress and sleep: Prudchenko IA et al., “DSIP and its analogs: sleep modulating properties,” various Russian clinical publications. Extensive Russian/Soviet-era clinical work demonstrating DSIP’s sleep-modulating and stress-buffering properties in human subjects.

Neuroendocrine effects: Kato N et al., demonstrated that DSIP modulates cortisol and ACTH release patterns, supporting its role in stress-related sleep disruption.

Related Protocols

• MK-677 Protocol — oral GH secretagogue that also improves sleep
• Selank Protocol — anxiolytic peptide for stress-related sleep issues
• Semax Protocol — cognitive peptide (complementary to DSIP for brain optimization)
• Peptide Safety Guide — injection technique, storage, general safety
• Reconstitution Calculator — dosing math for your vials